These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 8384277)
1. [Penetration into bone and joint tissues of rabbits and in vitro antibacterial activity of tosufloxacin]. Yamashiro Y; Nunome M; Takahata M; Yasuda T Jpn J Antibiot; 1993 Jan; 46(1):31-5. PubMed ID: 8384277 [TBL] [Abstract][Full Text] [Related]
2. [Studies on suppurative lesion and bone distribution of peroral antimicrobial agents (LAPC and TFLX) to experimental infected rabbits]. Tanaka M; Satoh T Shigaku; 1990 Oct; 78(3):527-52. PubMed ID: 2134803 [TBL] [Abstract][Full Text] [Related]
3. [Antibacterial activity of tosufloxacin against fresh clinical isolates]. Yamashiro Y; Shimakura M; Minami S; Fukuoka Y; Yasuda T; Watanabe Y; Narita H; Akama M Jpn J Antibiot; 1994 Mar; 47(3):245-54. PubMed ID: 8182895 [TBL] [Abstract][Full Text] [Related]
4. Diffusion of tosufloxacin into prostatic tissue. Uchibayashi T; Hisazumi H; Kanayama J; Kumano K Chemotherapy; 1992; 38(3):150-4. PubMed ID: 1380905 [TBL] [Abstract][Full Text] [Related]
6. [Antimicrobial activities of tosufloxacin against recently obtained clinical isolates]. Ishihara R; Suzuki Y; Tanaka S; Fukayama S; Deguchi K; Oda S; Nakane Y; Fukumoto T Jpn J Antibiot; 1996 Jul; 49(7):715-42. PubMed ID: 8828073 [TBL] [Abstract][Full Text] [Related]
7. [Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. Mikamo H; Tanaka K; Watanabe K Jpn J Antibiot; 2006 Dec; 59(6):468-73. PubMed ID: 17334064 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards]. Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183 [TBL] [Abstract][Full Text] [Related]
9. [The history of the development and changes of quinolone antibacterial agents]. Takahashi H; Hayakawa I; Akimoto T Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768 [TBL] [Abstract][Full Text] [Related]
10. Cross-resistance of clinical isolates of methicillin-resistant Staphylococcus aureus to aminoglycosides and fluoroquinolones. Uete T; Matsuo K; Uete G Jpn J Antibiot; 1992 Aug; 45(8):943-8. PubMed ID: 1433900 [TBL] [Abstract][Full Text] [Related]
11. [Morphological changes in penicillin-resistant Streptococcus pneumoniae and beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae after exposure to oral antibacterial agents]. Chiba N; Morozumi M; Ubukata K Jpn J Antibiot; 2012 Oct; 65(5):323-34. PubMed ID: 23383434 [TBL] [Abstract][Full Text] [Related]
12. [Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections]. Kobayashi I; Matsuzaki K; Omika K; Hasegawa M; Sato Y Jpn J Antibiot; 2007 Apr; 60(2):98-106. PubMed ID: 17612257 [TBL] [Abstract][Full Text] [Related]
13. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae]. Maekawa M; Fukuda Y; Sugiura Y; Kamiyama T; Futakuchi N; Takahata M; Mitsuyama J Jpn J Antibiot; 2003 Feb; 56(1):27-35. PubMed ID: 12723396 [TBL] [Abstract][Full Text] [Related]
14. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990. Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. Sato H; Fukuda S; Inatomi M; Koide R; Uchida N; Kanda Y; Kiuchi Y; Oguchi K Nippon Ganka Gakkai Zasshi; 1996 Jul; 100(7):513-9. PubMed ID: 8741334 [TBL] [Abstract][Full Text] [Related]
16. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Boos M; Mayer S; Fischer A; Köhrer K; Scheuring S; Heisig P; Verhoef J; Fluit AC; Schmitz FJ Antimicrob Agents Chemother; 2001 Mar; 45(3):938-42. PubMed ID: 11181385 [TBL] [Abstract][Full Text] [Related]
17. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. Noviello S; Ianniello F; Leone S; Esposito S J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672 [TBL] [Abstract][Full Text] [Related]
18. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens]. Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240 [TBL] [Abstract][Full Text] [Related]
19. [Lomefloxacin concentration in human prostatic tissue following 3-day administration]. Morita M; Hatakeyama T; Suzuki K Hinyokika Kiyo; 1993 Jan; 39(1):97-9. PubMed ID: 7681621 [TBL] [Abstract][Full Text] [Related]
20. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae. Ridgway GL; O'Hare MD; Felmingham D; Grüneberg RN Drugs Exp Clin Res; 1985; 11(4):259-62. PubMed ID: 2941258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]